nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLC22A6—Acetylsalicylic acid—Kawasaki disease	0.446	0.475	CbGbCtD
Dabrafenib—CYP2C8—Acetylsalicylic acid—Kawasaki disease	0.293	0.313	CbGbCtD
Dabrafenib—ABCB1—Acetylsalicylic acid—Kawasaki disease	0.199	0.212	CbGbCtD
Dabrafenib—LIMK1—heart—Kawasaki disease	0.00881	0.141	CbGeAlD
Dabrafenib—SIK1—cardiac ventricle—Kawasaki disease	0.00694	0.111	CbGeAlD
Dabrafenib—SIK1—myocardium—Kawasaki disease	0.00652	0.105	CbGeAlD
Dabrafenib—RAF1—cardiac ventricle—Kawasaki disease	0.00552	0.0886	CbGeAlD
Dabrafenib—RAF1—neck—Kawasaki disease	0.00549	0.088	CbGeAlD
Dabrafenib—BRAF—heart—Kawasaki disease	0.00544	0.0873	CbGeAlD
Dabrafenib—RAF1—myocardium—Kawasaki disease	0.00519	0.0833	CbGeAlD
Dabrafenib—SIK1—heart—Kawasaki disease	0.00455	0.0731	CbGeAlD
Dabrafenib—SIK1—skin of body—Kawasaki disease	0.00446	0.0716	CbGeAlD
Dabrafenib—RAF1—heart—Kawasaki disease	0.00363	0.0582	CbGeAlD
Dabrafenib—RAF1—skin of body—Kawasaki disease	0.00355	0.057	CbGeAlD
Dabrafenib—ABCG2—heart—Kawasaki disease	0.0015	0.0241	CbGeAlD
Dabrafenib—ABCB1—heart—Kawasaki disease	0.000739	0.0119	CbGeAlD
Dabrafenib—LIMK1—Regulation of actin dynamics for phagocytic cup formation—FCGR2A—Kawasaki disease	9.67e-06	0.0924	CbGpPWpGaD
Dabrafenib—LIMK1—Fcgamma receptor (FCGR) dependent phagocytosis—FCGR2A—Kawasaki disease	7.3e-06	0.0697	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—BLK—Kawasaki disease	6.88e-06	0.0657	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—ITPKC—Kawasaki disease	6.68e-06	0.0638	CbGpPWpGaD
Dabrafenib—BRAF—Integrin-mediated Cell Adhesion—ITGAE—Kawasaki disease	5.63e-06	0.0538	CbGpPWpGaD
Dabrafenib—RAF1—Integrin-mediated Cell Adhesion—ITGAE—Kawasaki disease	3.89e-06	0.0372	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—ITGAE—Kawasaki disease	3.37e-06	0.0322	CbGpPWpGaD
Dabrafenib—BRAF—B Cell Receptor Signaling Pathway—BLK—Kawasaki disease	3.07e-06	0.0293	CbGpPWpGaD
Dabrafenib—BRAF—PDGFR-beta signaling pathway—BLK—Kawasaki disease	2.5e-06	0.0239	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—CD4—Kawasaki disease	2.49e-06	0.0238	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—ITGAE—Kawasaki disease	2.33e-06	0.0223	CbGpPWpGaD
Dabrafenib—LIMK1—CXCR4-mediated signaling events—MMP9—Kawasaki disease	2.17e-06	0.0207	CbGpPWpGaD
Dabrafenib—BRAF—Bladder Cancer—VEGFA—Kawasaki disease	2.16e-06	0.0206	CbGpPWpGaD
Dabrafenib—RAF1—B Cell Receptor Signaling Pathway—BLK—Kawasaki disease	2.12e-06	0.0203	CbGpPWpGaD
Dabrafenib—LIMK1—EPH-Ephrin signaling—MMP9—Kawasaki disease	1.98e-06	0.0189	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—BLK—Kawasaki disease	1.79e-06	0.0171	CbGpPWpGaD
Dabrafenib—LIMK1—EPH-Ephrin signaling—VEGFA—Kawasaki disease	1.78e-06	0.017	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—BLK—Kawasaki disease	1.73e-06	0.0165	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—FCGR2A—Kawasaki disease	1.52e-06	0.0145	CbGpPWpGaD
Dabrafenib—RAF1—VEGFR2 mediated cell proliferation—VEGFA—Kawasaki disease	1.39e-06	0.0133	CbGpPWpGaD
Dabrafenib—RAF1—TWEAK Signaling Pathway—MMP9—Kawasaki disease	1.31e-06	0.0125	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CCR5—Kawasaki disease	1.3e-06	0.0124	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—BLK—Kawasaki disease	1.24e-06	0.0118	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-2-alpha transcription factor network—VEGFA—Kawasaki disease	1.21e-06	0.0116	CbGpPWpGaD
Dabrafenib—BRAF—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—Kawasaki disease	1.15e-06	0.011	CbGpPWpGaD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—VEGFA—Kawasaki disease	1.09e-06	0.0104	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ITPKC—Kawasaki disease	9.99e-07	0.00954	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CD40—Kawasaki disease	9.8e-07	0.00936	CbGpPWpGaD
Dabrafenib—RAF1—AGE/RAGE pathway—MMP9—Kawasaki disease	9.09e-07	0.00868	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—VEGFA—Kawasaki disease	9.05e-07	0.00865	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—FCGR2A—Kawasaki disease	8.84e-07	0.00844	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—BLK—Kawasaki disease	8.58e-07	0.00819	CbGpPWpGaD
Dabrafenib—RAF1—Oncostatin M Signaling Pathway—VEGFA—Kawasaki disease	8.26e-07	0.00789	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—CD4—Kawasaki disease	8.15e-07	0.00778	CbGpPWpGaD
Dabrafenib—RAF1—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—Kawasaki disease	7.97e-07	0.00761	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CRP—Kawasaki disease	7.89e-07	0.00753	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL10—Kawasaki disease	7.51e-07	0.00717	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—MMP9—Kawasaki disease	7.36e-07	0.00703	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD40—Kawasaki disease	7.13e-07	0.00681	CbGpPWpGaD
Dabrafenib—ABCG2—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	7.12e-07	0.0068	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ITPKC—Kawasaki disease	6.71e-07	0.00641	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—VEGFA—Kawasaki disease	6.61e-07	0.00631	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ITPKC—Kawasaki disease	6.21e-07	0.00593	CbGpPWpGaD
Dabrafenib—BRAF—Integrated Breast Cancer Pathway—VEGFA—Kawasaki disease	6.09e-07	0.00581	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—VEGFA—Kawasaki disease	5.55e-07	0.0053	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD4—Kawasaki disease	5.33e-07	0.00509	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—MMP9—Kawasaki disease	5.25e-07	0.00502	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—FCGR2A—Kawasaki disease	5.25e-07	0.00502	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—VEGFA—Kawasaki disease	5.24e-07	0.005	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—VEGFA—Kawasaki disease	5.06e-07	0.00484	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—MMP9—Kawasaki disease	4.95e-07	0.00473	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—BLK—Kawasaki disease	4.89e-07	0.00467	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—VEGFA—Kawasaki disease	4.72e-07	0.0045	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CRP—Kawasaki disease	4.59e-07	0.00439	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40—Kawasaki disease	4.06e-07	0.00388	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ITPKC—Kawasaki disease	3.86e-07	0.00368	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—Kawasaki disease	3.85e-07	0.00368	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—VEGFA—Kawasaki disease	3.5e-07	0.00335	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	3.49e-07	0.00333	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ITPKC—Kawasaki disease	3.36e-07	0.00321	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—VEGFA—Kawasaki disease	3.33e-07	0.00318	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—Kawasaki disease	3.1e-07	0.00297	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—Kawasaki disease	3.1e-07	0.00296	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FCGR2A—Kawasaki disease	3.06e-07	0.00292	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BLK—Kawasaki disease	2.97e-07	0.00283	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CRP—Kawasaki disease	2.73e-07	0.00261	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—MMP9—Kawasaki disease	2.55e-07	0.00243	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40—Kawasaki disease	2.47e-07	0.00235	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—Kawasaki disease	2.29e-07	0.00218	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CCR5—Kawasaki disease	2.28e-07	0.00218	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ITPKC—Kawasaki disease	2.07e-07	0.00198	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR5—Kawasaki disease	1.87e-07	0.00179	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—Kawasaki disease	1.84e-07	0.00176	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—Kawasaki disease	1.82e-07	0.00174	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—Kawasaki disease	1.77e-07	0.00169	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—Kawasaki disease	1.65e-07	0.00157	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—Kawasaki disease	1.63e-07	0.00156	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—Kawasaki disease	1.6e-07	0.00153	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—Kawasaki disease	1.6e-07	0.00153	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—Kawasaki disease	1.59e-07	0.00152	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—Kawasaki disease	1.58e-07	0.00151	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—Kawasaki disease	1.43e-07	0.00137	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—Kawasaki disease	1.1e-07	0.00106	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—Kawasaki disease	1.07e-07	0.00102	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—Kawasaki disease	9.91e-08	0.000946	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—Kawasaki disease	8.73e-08	0.000834	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—Kawasaki disease	7.84e-08	0.000749	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—Kawasaki disease	6.04e-08	0.000577	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—Kawasaki disease	5.43e-08	0.000518	CbGpPWpGaD
